Changing the Practice of Medicine
Popular
- NEW EPISODEMinuteCE®
Ongoing Trials in Oral Targeted Strategies in Breast Cancer
0.50 program credits
Aditya Bardia, MD, MPH, FASCO
- NEW EPISODEMinuteCE®
SERENA-6: Acting on ESR1 Mutations in Advanced Breast Cancer
0.50 program creditsErica L. Mayer, MD, MPH
- CME/CE Broadcast Replay
A Q-Challenge™ Replay: Advancing Precision Diagnosis and Treatment Strategies in Acromegaly
1.00 creditMaria Fleseriu, MD, FACE
Shlomo Melmed, MBChB
Elise M. Brett, MD, FACE
- Oncology and Hematology
TROPION-Breast02: Evidence for the Approval of Datopotamab Deruxtecan for Patients With mTNBC Ineligible for Immunotherapy
Tiffany Traina, MD, FASCO
- MinuteCE®
IBD Care Reimagined: Personalized, Proactive, and Target-Driven Management
2.00 credits 3 episodesDavid T. Rubin, MD
Michael Dolinger, MD, MBA
Florence Odufalu, MD
Ugo Iroku, MD, MHS
Sharon Dudley-Brown, PhD, FNP-BC, FAAN, FAANP
- MinuteCE®
Choosing the Path Forward: A Real-World Dialogue on Perioperative Immunotherapy
0.50 program creditsAdam J. Luginbuhl, MD
Jennifer Johnson, MD, PhD
Adam J. Luginbuhl, MD
CME/CE
- NEW EPISODEMinuteCE®
ELEVATE: Elacestrant Plus Capivasertib in Advanced Breast Cancer
0.50 program creditsAditya Bardia, MD, MPH, FASCO
- CME/CE Broadcast Replay
Seeing the Invisible: Radiologic Precision to Enable Early Intervention in Bronchiectasis
1.00 creditRobert D. Suh, MD
Ashwin Basavaraj, MD
Mary Salvatore, MD, MBA
Jennifer Johnson, MD, PhD
Jennifer Johnson, MD, PhD
David T. Rubin, MD
Michael Dolinger, MD, MBA
Sharon Dudley-Brown, PhD, FNP-BC, FAAN, FAANP
Florence Odufalu, MD
Clinical Practice
Aditya Bardia, MD, MPH, FASCO
Erica L. Mayer, MD, MPH
Neeraj Agarwal, MD, FASCO
Rana McKay, MD
Michael Dolinger, MD, MBA
Florence Odufalu, MD
- MinuteCE®
IBD Masterclass: Foundations of Pathophysiology and Targeted Therapy
1.00 credit 7 episodesDavid T. Rubin, MD
Michael Dolinger, MD, MBA
Florence Odufalu, MD
Ugo Iroku, MD, MHS
Sharon Dudley-Brown, PhD, FNP-BC, FAAN, FAANP
David T. Rubin, MD
Ugo Iroku, MD, MHS
Programs
- Oncology and Hematology
DESTINY-Breast05 Findings Lead to New Indication for Trastuzumab Deruxtecan as Adjuvant Treatment for Residual Invasive Disease
Sara A. Hurvitz, MD, FACP
- Oncology and Hematology
DESTINY-Breast11: Trastuzumab Deruxtecan Followed by THP Yields New Indication in the Neoadjuvant Setting.
Sara A. Hurvitz, MD, FACP
Adam J. Luginbuhl, MD
Jennifer Johnson, MD, PhD
David T. Rubin, MD
Michael Dolinger, MD, MBA